GlassScriptPhysician profile
Andrew J Donati
NPI 1730543653
$3,553.58
in general payments reported to CMS, 2019-2025
31 companies · $947 in 2025
The $947 reported for 2025 was more than what 76% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $88.99 · 2022: $579 · 2023: $1,004 · 2024: $934 · 2025: $947.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,703 · Education: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,702.66 |
| Education | $182.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $452.94 | 2022-2025 | Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $416.26 | 2021-2025 | |
| Travere Therapeutics, INC. | $284.35 | 2022-2025 | Filspari |
| Astrazeneca Pharmaceuticals LP | $282.38 | 2022-2025 | Farxiga, Lokelma |
| Novartis Pharmaceuticals Corporation | $252.63 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $214.17 | 2023-2025 | Jardiance |
| Xeris Pharmaceuticals, INC. | $141.09 | 2024-2025 | Keveyis |
| Amgen INC. | $131.95 | 2024-2025 | Uplizna, Aranesp, Tavneos |
| Otsuka America Pharmaceutical, INC. | $119.40 | 2022-2023 | Jynarque |
| Novo Nordisk INC | $114.32 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Vifor Pharma, INC. | $106.94 | 2022-2024 | Veltassa |
| Akebia Therapeutics INC | $96.94 | 2021-2024 | Auryxia, Vafseo |
| Calliditas Therapeutics US INC. | $96.69 | 2022-2025 | Tarpeyo |
| Alexion Pharmaceuticals, INC. | $89.26 | 2022-2025 | Ultomiris |
| Pfizer INC. | $88.12 | 2023-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $77.48 | 2021-2024 | Lupkynis |
| Glaxosmithkline, LLC. | $75.50 | 2022-2024 | Jesduvroq, Benlysta |
| Ani Pharmaceuticals, INC. | $65.45 | 2025 | Purified Cortrophin Gel |
| Baxter Healthcare | $64.48 | 2022-2025 | Renal - Pd |
| Fresenius USA Marketing, INC. | $55.02 | 2022-2023 | Velphoro |
| Genzyme Corporation | $49.39 | 2021-2023 | |
| Ardelyx, INC. | $48.41 | 2024-2025 | Ibsrela |
| Opko Pharmaceuticals, LLC | $42.76 | 2022-2025 | Rayaldee |
| Ultragenyx Pharmaceutical INC. | $38.28 | 2022-2023 | |
| Ascendis Pharma Endocrinology INC | $29.01 | 2025 | Yorvipath |
| Takeda Pharmaceuticals U.S.A., INC. | $25.37 | 2023 | Gattex |
| Nxstage Medical, INC. | $24.03 | 2022 | |
| Rhythm Pharmaceuticals, INC. | $19.93 | 2025 | Imcivree |
| Azurity Pharmaceuticals, INC. | $18.76 | 2023 | Horizant |
| Horizon Therapeutics Plc | $17.22 | 2023 | Krystexxa |
| Scpharmaceuticals INC. | $15.05 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Donati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.